RESULTS	Obliterative bronchiolitis developed in significantly fewer patients in the tacrolimus group ( 21.7 % ) compared with the cyclosporine group ( 38 % ) ( p = 0.025 ) , and there was greater freedom from obliterative bronchiolitis over time for patients receiving tacrolimus ( p < 0.03 ) .\